Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0366 • ACR Convergence 2022
Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia
John McKinnon¹, Joel Santiaguel², Claudia Murta De Oliveira³, Dongzi Yu⁴, Mukhy Khursheed⁵, Flavie Moreau⁶, Lena Klopp-Schulze⁷, Jamie Shaw⁸, Sanjeev Roy⁹ and Amy Kao¹⁰, ¹Department of Medicine, Henry Ford Hospital, Detroit, MI, ²Internal Medicine, Quirino Memorial Medical Center, Quezon City, Philippines, ³Ambulatório de Pesquisa Clínica, Santa Casa de Misericórdia, Belo Horizonte, Brazil, ⁴Global Clinical Development, EMD Serono, Billerica, MA, ⁵Global Patient Safety, Merck Serono Ltd., an affiliate of Merck KGaA, Darmstadt, Germany, ⁶Global Biostatistics, EMD Serono, Billerica, MA, ⁷Translational Medicine, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Translational Medicine, EMD Serono, Billerica, MA, ⁹Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, ¹⁰EMD Serono, Billerica, MA
Background/Purpose: Enpatoran is a selective and potent dual toll-like receptor (TLR) 7/8 inhibitor in development for the treatment of cutaneous and systemic lupus erythematosus (CLE/SLE).…
Abstract Number: 0631 • ACR Convergence 2022
Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease
Emily Vara, Dulaney Wilson, John Pearce, Jim Oates and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Perfluoroalkyl substances (PFAS) are a class of persistent organic pollutants found in nonstick products, water repellant fabrics, fire-retardant foams, and food packaging. Highly stable,…
Abstract Number: 0649 • ACR Convergence 2022
Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity
Marc Scherlinger¹, Wenliang Pan², Ryo Hisada¹, Milena Vukelic³, Masataka Umeda¹, Afroditi Boulougoura², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a defective T regulatory (Treg) cell compartment which participate in immune dysregulation. Although the underlying mechanism are…
Abstract Number: 0669 • ACR Convergence 2022
Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus
Thomas Li¹, Ethan Seltzer¹, Victoria Zyulina¹, Keila Veiga², Noa Schwartz³, Yurii Chinenov¹, David Oliver¹, Jose Lora⁴, Ali Jabbari⁵, Yong Liu¹, Hafsa Munir¹, William Shipman¹, Marvin Sandoval¹, Isabel Sollohub¹, william ambler¹, Bikash Mishra⁴, sarah taber¹, karen onel¹, Mehdi Rashighi⁶, james krueger⁷, Niroshana Anandasabapathy⁴, Carl Blobel¹ and theresa Lu¹, ¹Hospital for Special Surgery, New York, NY, ²Maria Fareri Children's Hospital, New York, NY, ³Albert Einstein College of Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵University of Iowa, Iowa City, IA, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷Rockefeller University, New York, NY
Background/Purpose: Photosensitivity is a hallmark symptom of lupus erythematosus (LE), in which patients develop inflammatory skin lesions in response to ultraviolet radiation (UVR). In examining…
Abstract Number: 0949 • ACR Convergence 2022
Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience
Joo Young (Esther) Lee¹, Arielle Mendel², Anca Askanase³, Sang-Cheol Bae⁴, Jill Buyon⁵, Ann E Clarke⁶, Nathalie Costedoat-Chalumeau⁷, Paul R Fortin⁸, Dafna Gladman⁹, John Hanly¹⁰, Murat Inanc¹¹, David Isenberg¹², Anselm Mak¹³, Marta Mosca¹⁴, Michelle Petri¹⁵, Anisur Rahman¹⁶, Rosalind Ramsey-Goldman¹⁷, Jorge Sanchez-Guerrero¹⁸, Murray Urowitz¹⁹, Daniel Wallace²⁰, Sasha Bernatsky²¹ and Evelyne Vinet², ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³Columbia University Medical Center, New York, NY, ⁴Hanyang University Medical Center, Seoul, Republic of Korea, ⁵NYU Grossman School of Medicine, New York, NY, ⁶University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁷Inserm DR Paris 5, Paris, France, ⁸Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁰Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ¹¹Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, ¹²University College London, London, United Kingdom, ¹³Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁶Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁷Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ¹⁸Sinai Health System, Toronto, ON, Canada, ¹⁹University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ²⁰Cedars-Sinai Medical Center, Los Angeles, CA, ²¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: One-third of women with SLE develop lupus nephritis (LN), and most receive mycophenolate mofetil (MMF). However, MMF is teratogenic, and needs to be switched…
Abstract Number: 0976 • ACR Convergence 2022
Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
Alvaro Gomez¹, Sandra Jägerback¹, Christopher Sjöwall² and Ioannis Parodis³, ¹Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Renal flares contribute substantially to morbidity, renal survival and death in systemic lupus erythematosus (SLE). Identification of pharmacological strategies for the prevention of renal…
Abstract Number: 0993 • ACR Convergence 2022
SARS-CoV-2 Vaccine Side Effects and Infections in SLE
Laura Yan¹, Arielle Mendel², Evelyne Vinet², Fares Kalache³, Jennifer Lee¹, Popi Panaritis² and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Center, Montréal, QC, Canada
Background/Purpose: SLE patients are an especially vulnerable population in the face of the COVID pandemic due to their dysregulated endogenous immune system, further downregulated by…
Abstract Number: 1118 • ACR Convergence 2022
Monocyte Transcriptomic Analysis Uncovers Heterogeneous Gene Expression Profiles in Systemic Lupus Erythematous (SLE) with and Without Subclinical Atherosclerosis
Laurel Woodridge¹, Elvira Chocano Navarro², George Robinson¹, Paul Ashford¹, Kirsty Waddington³, Anisur Rahman⁴, Christine Orengo⁵, Ines Pineda-Torra⁶ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²VIHR, Barcelona, Spain, ³University College London (alumni), London, United Kingdom, ⁴Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵ISMB / UCL, London, United Kingdom, ⁶Cabimer, Sevilla, Spain
Background/Purpose: A leading cause of mortality in SLE is cardiovascular disease (CVD) through accelerated atherosclerosis: the build-up of cells and lipids in the vascular wall.…
Abstract Number: 1297 • ACR Convergence 2022
A Paediatric-Adult Provider Dyad Care Model Improves Transition from Paediatric to Adult Health Care for Youth with Childhood-Onset Systemic Lupus Erythematosus
Tala El Tal¹, Abdulaziz el Mutairi¹, Amanda Steiman² and Earl Silverman³, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²Sinai Health System, Toronto, ON, Canada, ³The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease affecting 1 in 1000 individuals, of whom 20% develop the disease in childhood. Childhood-onset…
Abstract Number: 1381 • ACR Convergence 2022
Health Related Quality of Life in Children with Systemic Lupus Erythematosus
Julie Samuels¹, Rula Issa², Lauren Robinson³ and Rebecca Trachtman¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Phillips School of Nursing at Mount Sinai, New York, NY, ³Hospital for Special Surgery/New York Presbyterian-Weill Cornell, New York, NY
Background/Purpose: The importance of patient-reported outcomes and health-related quality of life (HRQOL) is increasingly recognized in healthcare. Adults with Systemic Lupus Erythematosus (SLE) have poor…
Abstract Number: 1454 • ACR Convergence 2022
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
Sarah Reid¹, Johanna K Sandling¹, Pascal Pucholt¹, Ahmed Sayadi¹, Christopher Sjöwall², Karoline Lerang³, Andreas Jönsen⁴, Anders A Bengtsson⁴, Øyvind Molberg³, Anna Rudin⁵, Solbritt Rantapää-Dahlqvist⁶, Lars Ronnblom⁷ and Dag Leonard¹, ¹Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁶Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁷Uppsala University, Uppsala, Sweden
Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
Abstract Number: 1474 • ACR Convergence 2022
Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE
Erik Anderson, Chris Tang, An Vo, Cynthia Aranow, Bruce Volpe, Betty Diamond and Meggan Mackay, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Stimulation of the kynurenine/tryptophan pathway by interferons alpha and gamma, both known contributors to SLE pathogenesis, leads to a potentially neurotoxic imbalance of pathway…
Abstract Number: 1595 • ACR Convergence 2022
Association of Sustained Lupus Low Disease Activity State with Improved Outcomes in SLE: A Multinational Prospective Cohort Study
Vera Golder¹, Rangi Kandane-Rathnayake¹, Ning Li¹, Worawit Louthrenoo², Yi-Hsing Chen³, Jiacai Cho⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Luo Shue Fen⁷, Yeong-Jian Wu⁷, Sandra Navarra⁸, Leonid Zamora⁸, Zhanguo Li⁹, An Yuan¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhouli Zhang¹⁴, Duminda Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Fiona Goldblatt²⁰, Shereen Oon²¹, Sean O'Neill²², Kathryn Gibson²², Kristine Ng²³, Hui Nee Annie Law²⁴, Nicole Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Yoshiya Tanaka²⁸, Chak Sing²⁹, Alberta Hoi³⁰, Mandana Nikpour³¹ and Eric Morand³², ¹Monash University, Clayton, Australia, ²Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ⁴National University Health System (NUHS), Singapore, Singapore, ⁵National University Hospital, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸University of Santo Tomas, Manila, Philippines, ⁹Peking University People's Hospital, Beijing, China, ¹⁰Peking University Health Science Center, Beijing, China, ¹¹University of Malaya, Kuala Lumpur, Kuala Lumpur, Malaysia, ¹²Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹³The University of Melbourne, Melbourne, Australia, ¹⁴Peking University First Hospital, Beijing, China, ¹⁵Teaching Hospital Kandy, Kandy, Sri Lanka, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Keio University School of Medicine, Tokyo, Japan, ¹⁸Keio University and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Medical Center, Seoul, Republic of Korea, ²⁰Flinders Medical Centre, Adelaide, Australia, ²¹St Vincent's Hospital, Fitzroy, Australia, ²²Liverpool Hospital, Sydney, Australia, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁵Greenlane Clinical Centre, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Quezon City, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²⁹The University of Hong Kong, Pok Fu Lam, Hong Kong, ³⁰Monash Health, Melbourne, Australia, ³¹The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³²Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Since the initial prospective validation of the Lupus Low Disease Activity State (LLDAS), this treat-to-target endpoint has been studied in numerous other cohorts, with…
Abstract Number: 1709 • ACR Convergence 2022
Role of Corneal Langerhans Dendritic Cells in Lupus Keratitis
Ram Singh¹ and Angel Gutierrez², ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA
Background/Purpose: Patients with lupus and other systemic autoimmune diseases develop ocular surface inflammation that is sometimes severe and debilitating. Pathogenesis of autoimmune keratitis remains unclear.…
Abstract Number: 1779 • ACR Convergence 2022
Psychosocial and Health Measures in Systemic Lupus Erythematosus: COVID-19 Pandemic Trends in the Georgians Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao², Jessica Williams², S. Sam Lim¹ and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic may have a sustained impact on systemic lupus erythematosus (SLE) patients in multiple ways. In a large predominantly Black SLE cohort,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].